Comparison of Outcomes in Patients with Stage III versus Limited Stage IV Non-Small Cell Lung Cancer
Standard therapy for metastatic non small cell lung cancer (NSCLC) includes palliative systemic chemotherapy and/or radiotherapy. Recent studies of patients with limited metastases treated with curative-intent stereotactic body radiation therapy (SBRT) have shown encouraging survival.
We hypothesized that patients treated with SBRT for limited metastases have comparable outcomes with those treated with curative-intent radiation for Stage III NSCLC.
Methods:
We retrospectively reviewed the records of NSCLC patients treated with curative-intent radiotherapy at the University of Rochester from 2000-2008. We identified 3 groups of patients with NSCLC: stage III, stage IV, and recurrent stage IV (initial stage I-II).
All stage IV NSCLC patients treated with SBRT had [less than or equal to]8 lesions.
Results:
Of 146 patients, 88% had KPS >80%, 30% had >5% weight loss, and 95% were smokers. The 5-year OS from date of NSCLC diagnosis for stage III, initial stage IV and recurrent stage IV was 7%, 14%, and 27% respectively.
The 5-year OS from date of metastatic diagnosis was significantly (p<0.00001) superior among those with limited metastases (less than or equal to8 lesions) versus stage III patients who developed extensive metastases not amenable to SBRT (22% vs. 0%).
Conclusions:
Stage IV NSCLC is a heterogeneous patient population, with a selected cohort apparently faring better than Stage III patients.
Though patients with limited metastases are favorably selected by virtue of more indolent disease and/or less bulky disease burden, perhaps staging these patients differently is appropriate for prognostic and treatment characterization. Aggressive local therapy may be indicated in these patients, though prospective clinical studies are needed.
Author: Praveena CheruvuSu MetcalfeJustin MetcalfeYuhchyau ChenPaul OkunieffMichael Milano
Credits/Source: Radiation Oncology 2011, 6:80
Published on: 2011-06-30
Copyright by the authors listed above - made available via BioMedCentral (Open Access). Please
make sure to read our disclaimer prior to contacting 7thSpace Interactive. To contact our editors, visit our online helpdesk. If you wish submit your own press release, click here.
Social Bookmarking
RETWEET This! | Digg this! | Post to del.icio.us | Post to Furl | Add to Netscape | Add to Yahoo! | Rojo
|
|
